BRAWN BIOTECH LTD.

Brawn Biotech Ltd has announced the closure of its trading window for designated persons and their immediate relatives. This closure is in effect from July 1, 2026, until 48 hours after the declaration of the Un-Audited Financial Results for the quarter ended June 30, 2026. The company has advised insiders not to trade in its securities during this period. The exact date of the board meeting to consider these results will be communicated later.

Brawn Biotech Ltd. reports that Regulation 23(9) concerning the filing of related party transactions is not applicable for the year ended March 31, 2026. As of March 31, 2026, the company's paid-up share capital was ₹3 Crores and net worth was approximately ₹4.32 Crores. This exemption is based on Regulation 15(2) of SEBI (Listing Obligation and Disclosure Requirement) Regulations, 2015, as the company's financials remained below the threshold of ₹10 Crore paid-up capital and ₹25 Crore net worth for the last three consecutive financial years.

Brawn Biotech Ltd's Board of Directors approved the audited financial results for the quarter and year ended March 31, 2026, in a meeting held on May 29, 2026. The company's revenue from operations for the year ended March 31, 2026, stood at ₹1,743.18 Lacs. The meeting commenced at 3:30 PM and concluded at 4:00 PM. The results have been prepared in compliance with Indian Accounting Standards.

Brawn Biotech Ltd. announced the audited financial results for the quarter and year ended 31st March 2026. The Board of Directors approved the results in their meeting held on 29th May 2026. Revenue from operations for the year ended March 31, 2026, stood at ₹1,697.77 Lacs. The meeting commenced at 3:30 PM and concluded at 4:00 PM.

Brawn Biotech Ltd has announced a meeting of its Board of Directors scheduled for May 29, 2026, to consider and approve the audited financial results for the quarter and financial year ended March 31, 2026. The trading window, which was closed on March 30, 2026, will remain closed until May 31, 2026, and will reopen on June 1, 2026.

Brawn Biotech Ltd has announced the closure of the Trading Window for Designated Persons and their immediate relatives from 01st April 2026 till 48 hours after the declaration of Audited financial results for the quarter and financial year ended 31st March 2026. This decision is in accordance with the Company's Code of Conduct to Regulate, Monitor and Report Trading by Insiders, as per the SEBI (Prohibition of Insider Trading) Regulations, 2015. Insiders are advised not to deal in securities of the Company during the closure of the Trading Window. The date of the Board meeting for result declaration will be intimated in due course.

Brawn Biotech Ltd has appointed Mr. Viney, a Practicing Company Secretary, as the Secretarial Auditor and M/s Sahil Pasricha & Associates, a Chartered Accountant firm, as the Internal Auditors for the financial year 2025-26. The appointments were made based on the recommendation of the Audit Committee and were approved at the Board meeting held on 25th March 2026. Mr. Viney is an Associate Member of the Institute of Company Secretaries of India with expertise in corporate laws, securities laws, and compliance management. M/s Sahil Pasricha & Associates offers a full range of services including Audit under Companies Act, Income Tax, GST Audit, Delhi VAT Act, Internal Audit, Consultancy in Taxation related matters, Company Law matters, Labour Laws, etc.

Brawn Biotech Ltd. announced its unaudited financial results for the quarter and year-to-date ended 31st December 2025. The Board of Directors approved the results in a meeting held on 14th February 2026. The company reported a net profit from ordinary activities after tax for the quarter at Rs. 1,205 Lakhs and Rs. 12,813 Lakhs for the nine-month period. The earnings per share (after extraordinary items) for the quarter is Rs. 1.50.

Brawn Biotech Ltd. has released its unaudited financial results for the quarter and nine months ended 31st December 2025. The board of directors approved the results in a meeting held on 14th February 2026. The company, primarily engaged in the pharmaceuticals business, reported a net profit from ordinary activities after tax for the period.

Brawn Biotech Ltd has appointed Ms. Rati Garg as the Chief Financial Officer (CFO) and Key Managerial Personnel. The appointment is in accordance with Regulations 30 of the Listing Regulations and the SEBI Circular No. SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July 2023. Ms. Garg, a qualified Cost Accountant, brings over 15 years of experience in financial management, cost control, budgeting, and regulatory compliance. She excels in financial planning & analysis, cost optimization, internal controls, statutory and cost audits, taxation, and corporate finance.